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ABSTRACT
Background. T-lymphocyte depletion is a strategy to reverse the impact of ischemia-
reperfusion injury (IRI) in progression to chronic allograft dysfunction, especially among
patients at high risk for delayed graft function (DGF).
Methods. The present work assessed the effect of thymoglobulin among a population
with a high incidence of DGF. We analyzed 209 transplanted patients: 97 in the
thymoglobulin and 112 in the control group.
Results. The main complication was DGF (59.3%), with a similar incidence in both
groups (63.9% vs 55.3%; P  .36). Acute rejection episodes (ARE) were decreased with
thymoglobulin (8.2% vs 28.5%; P  .001), but cytomegalovirus viremia was 3.4-fold more
frequent (58.3% vs 17.1%; P .001). One-year graft function was significantly better in the
thymoglobulin group (59.2  17.2 vs 51.8  15.3 mL/min; P  .004), even when censored
by ARE (59.7  17.5 vs 53.3  14.4; P  .023). The same difference was observed at the
2-year follow-up (P  .024), even when censored for ARE (P  .045). A multivariate
analysis showed thymoglobulin to be a factor strongly associated with protection of graft
function (P  .039).
Conclusion. Despite not reducing the incidence of DGF, thymoglobulin induction
significantly reduced the incidence of ARE and showed a long-term profile of protection
of renal graft function, independent of the reduction in ARE.
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vISCHEMIA and reperfusion injury (IRI) is a frequentevent in transplantation of kidneys from deceased do-
nors.1 Its clinical manifestation is delayed graft function
DGF), which increases risk of acute rejection episodes
ARE). Both events are linked to adverse short- and
ong-term outcomes.2 Chronic allograft nephropathy, the
main cause of kidney graft loss, represents the histologic
sequelae of a series of insults, According to Nankivell et al,3
early tubulointerstitial damage is correlated with immuno-
logical factors such as ARE, with the addition of IRI. Many
experimental studies have shown the role of T cells, specif-
ically CD4 elements, in the IRI process.4–6 Therefore, the
se of polyclonal antibodies that deplete CD4 T lympho-
cytes could be beneficial to prevent or attenuate IRI
effects.7,8 Goggins et al9 showed that an antithymocyte
globulin (ATG) dose before revascularization significantly
reduced the occurrence of DGF. However, Brennan et al10
failed to observe a decrease in DGF incidence when the
injury was associated with prolonged cold ischemia. We
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2428ave shown previously that patients who received thymo-
lobulin displayed improved graft function up to 1 year
fter transplantation, although this treatment did not pre-
ent DGF.11 We thus further investigated a cohort of
patients who received an induction protocol with an intra-
operative dose of thymoglobulin, followed by sequential
doses. We demonstrated that evolution of long-term graft
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THYMOGLOBULIN AND LONG-TERM FUNCTION 2429function was significantly better among the patient group
with induction treatment.
PATIENTS AND METHODS
Inclusion Criteria
We performed a historical cohort study of subjects who underwent
transplantation using kidneys from deceased donors. Eligible re-
cipients were patients 18 years old who were transplanted
between January 2002 and June 2005 at one of the following
institutions: Transplant Service divisions of Hospital São Paulo,
Hospital do Rim e Hipertensão (Federal University of São Paulo),
or Albert Einstein Israeli Hospital. The 672 transplants employed
kidneys from deceased donors excluded 44 patients owing to
transfer to another center, or because they were following a
different research protocol at the time of data collection. A further
321 patients were excluded because they used azathioprine for
initial immunosuppression, 35 who received induction with a
different protocol, or 63 participated in previous clinical trials.
Thus, 209 participants in this study included 97 who received the
induction protocol versus the remaining 112 controls.
Variables and Definitions
The complications considered were DGF, ARE, infection within
the first year, cytomegalovirus (CMV) infection, graft loss, and
death. DGF was defined as the need for dialysis within the first
postoperative week. Episodes of infection were defined as the
necessity of antibiotic, antifungicide, or antiviral treatments, only
when occurring within the first year posttransplant. CMV infections
were analyzed separately. Graft loss was defined as the need to
return to dialysis. ARE was always diagnosed by biopsy. To
diagnose a CMV infection, an antigenemia assay showed the
presence of pp6512; we adopted a strategy of preemptive treatment
for high-risk patients.
Induction Protocol and Baseline Immunosuppression
The polyclonal antibody was thymoglobulin (Genzyme, Cambridge,
Mass). All patients received prednisone and 1 mycophenic acid
Table 1. Demographic Data
Variables
Total
(n  209)
Age (yrs) 44.9  13.7
Gender, male (%) 52.6
Etiology of CRD
Unknown 45.4
Glomerulonephritis 16.2
Hypertension 9.09
Diabetes 17.2
Polycystic 5.7
Urologics 5.2
Retransplant 4.7
Donor age (yrs) 39.0  14.7
Donor gender, male (%) 52.2
PRA 7.8  18.1
MM 3.0  1.3
Time in dialysis (mos) 47.3  30.6
CIT (h) 21.7  6.9
Tac/Cya (%) 46.8/45.0Abbreviations: PRA, panel-reactive antibody; MM, missmatches; CIT, cold ischemtype (mofetil or sodium). The protocol consisted of an intraoper-
ative dose9 of 1.5 mg/kg of body weight, followed by sequential
doses of 1.0 mg/kg according to the total lymphocyte or CD3
T-lymphocyte counts. The duration of therapy with thymoglobulin
varied according to the duration of DGF. Administration of
calcineurin inhibitors was initiated when serum creatinine was
below 5.0 mg/dL, or when urinary flow reached 2.0 L/d, or when the
total doses of thymoglobulin had been administered. All patients
received mycophenolic acid, corticosteroids, and a calcineurin
inhibitor. The choice of calcineurin inhibitor is demonstrated in
Table 1. The calcineurin inhibitor was adjusted to the fasting levels,
and mycophenolate dose according to the side effects of leukopenia
and gastrointestinal symptoms. All patients received prophylaxis
against infection with Pneumocistis carinii with sulphamethoxazole-
trimethroprim (400/80 mg) once a day until 6 months postopera-
tively.
Renal Function Assessment
Creatinine clearance (CrCl), as a measure of renal graft function in
mL/min was estimated by the Cockroft-Gault formula. Two param-
eters were compared consistent with previous publications13,14:
Intercept and slope. On a Cartesian plot, intercept corresponded
with the CrCl value on the y axis, which each patient reached at a
certain time on the x axis. Slope measured the functional variation
between 2 contiguous or distinct times; its measurement correlated
with the speed of progression to graft loss. The differences between
6 months and 1 year, or between 1 and 2 years were used in the
present investigation.
Statistical Analysis
For data presentation, numerical variables were expressed as average
values and standard deviations in all situations, and categorical
variables were shown as percentages. For data comparisons between
the groups, we employed Student’s t-test for normally distributed
and Mann–Whitney U-test for non-normal distributions. The cat-
egorical variables were compared using the chi-square or Fisher’s
tests. Curves of graft function were generated from the mean
values of CrCl at each defined period, for comparison according to
ording Induction Therapy
Thymoglobulin
(n  97)
Control
(n  112) P
45.2  12.9 44.7  14.4 .78
50.5 54.4 .94
42.2 48.2 .95
20.6 12.5 .16
3.0 3.5 .75
15.4 18.7 .91
6.1 5.3 .92
5.1 5.3 .81
4.1 5.3 .94
38.7  14.1 39.9  14.3 .43
54.6 50.8 .76
10.2  20.5 6.6  16.7 .25
2.9  1.1 3.0  1.5 .45
46.3  33.4 48.1  28.3 .68
22.5  6.8 21.0  6.9 .17
46.3/44.3 47.3/45.5 .88, Accia time; Tac, tacrolimus; Cya, cyclosporine.
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2430 REQUIÃO-MOURA, FERRAZ, MATOS ET ALinduction or otherwise. The variables related to the risk of a worse
intercept at 1 year were analyzed using the intercept of 55 mL/min
as a cutoff, representing the average graft function value for all
patients at 1 year. Univariate analysis for the risk estimate was
performed using prevalence ratios, whereas multivariate analysis
employed stepwise forward binary logistic regression. The software
for statistical calculations was SPSS 12.0 for Windows (SPSS, Inc.,
Chicago, Ill). P .05 was considered significant within a confidence
interval (CI) of 95%.
RESULTS
Demographic Data
Demographic data are shown in Table 1. There were no
differences in the preoperative demographic variables ac-
cording to the presence or absence of induction. A total of
7.62 3.62 doses of thymoglobulin were administrated with
72.1% (n  70) of patients followed using CD3 counts.
Tacrolimus was used as the calcineurin inhibitor in 46.8%
of cases, with no difference between the 2 groups. The mean
follow-up time was 28.0  16.2 months.
Fig 1. (A)Curves of graft function
according induction therapy. Full
line, induction group; interrupted
line, control. *P .004; **P .024.
(B) Slopes of graft function accord-
ing induction therapy between 6
and 12 months (left) and 12 and 24
months (right). Full line, induction
group; interrupted line, control.
†P  .03; ‡P  .001. Values in
graphic are presented as average
standard error.Complications
The incidence of DGF was 59.3% (n  124) with patients
remaining on dialysis for an average of 12.6  11.1 days.
The use of immunologic induction did not reduce the
frequency of DGF: 63.9% in induced versus 55.3% in
controls (P  .36). The use of thymoglobulin had no
impact on the dialysis time during DGF (11.8  8.8 vs
13.5  13.3 days; P  .41). The use of antibody signifi-
cantly reduced the occurrence of ARE from 28.5% (n 
32) to 8.2% (n  8) (P  .001). One-year graft survival
was similar in both groups: thymoglobulin (93.4%) and
control (90.4%; P  .30). At the end of follow-up, graft
loss occurred in 9.5% (n  20) of all patients, being
.04-fold more frequent among the control group (12.0%
s 6.1%; P  .31).
CMV infection was the most serious complication of
hymoglobulin treatment. The screening of asymptomatic
nfection with weekly CMV antigenemia assays detected an
ncidence 3.4-fold greater among the induced patients:
8.3% in the induced versus 17.1% in the controls (P 
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THYMOGLOBULIN AND LONG-TERM FUNCTION 2431.001). The incidences of bacterial, fungal, and other viral
infections were similar for both groups. Among all patients,
58% had 1 infectious event within the first year; in the
ontrol group, the rate was 49.1% and in the induction
roup 51.5%. Incidence was also similar; 1.0  1.3 infec-
tions per patient per year in the control versus 0.9  1.2 in
the induction group (P  NS). Twenty-six patients died; 9
thymoglobulin (9.2%), while the remaining 17 (15.1%)
received no thymoglobulin.
Evolution of Graft Function According to Induction
Figure 1A shows that the estimated ClCr was similar in both
groups at 1 month posttransplantation, reflecting a similar
incidence of DGF: Induction 21.0  14.8 versus control
2.9 16.5 mL/min (P .42). Thereafter, there was a clear
eviation of the curves, pointing to a significant difference
fter 1 year of follow-up. The intercept in the thymoglobu-
in cohort was 59.2  17.2 mL/min, whereas for the control
roup it was 51.8  15.3 mL/min (P  .004), a difference
hat remained significant at 2 years: 59.6  17.1 versus
2.0  16.0 mL/min, respectively (P  .024). The slopemong thymoglobulin patients was positive in the 2 periods
Fig 1B):1.9 10.4 mL/min between 6 months and 1 year
nd 0.8  9.0 mL/min between 1 and 2 years, versus the
endency for progression to graft loss by 6 months in the
ontrol group 0.8 8.6 mL/min (P .03) and3.9 7.2
L/min (P  .001) respectively. Figure 2A shows that the
ntercept of the induction group among patients without an
RE, was significantly better than among affected subjects:
9.7  17.5 versus 53.3  14.4 mL/min (P  .023), a
ifference that remained significant at 2 years: 60.4  17.2
ersus 53.1  15.5 mL/min (P  .045). The slopes among
atients without ARE (Fig 2B) remained positive after 6
onths, 2.0  10.5 mL/min, and at 1 year posttransplan-
ation, 0.7  9.1 mL/min. In contrast, the control group
evealed a negative slope at the 2 times: 0.09  8.4
L/min (P  .13) and 3.3  6.7 mL/min (P  .003),
espectively.
We considered baseline characteristics among patients
ho did not experience an ARE, observing no significant
ifferences in recipient or donor age, recipient or donor
ender, HLA mismatched, time on prior dialysis cold
Fig 2. (A) Curves of graft func-
tion according induction therapy
censored by acute rejection epi-
sodes. Full line, induction group;
interrupted line, control. *P 
.023; **P  .045. (B) Slopes ac-
cording induction therapy be-
tween 6 and 12 months (left) and
12 and 24 months (right) cen-
sored by acute rejection. Full line,
induction group; interrupted line,
control. †P  .13 and ‡P  .003.
Values are presented as average
standard error.
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2432 REQUIÃO-MOURA, FERRAZ, MATOS ET ALischemia time, or panel-reactive antibodies. Calcineurin
inhibitor drug concentrations were also similar (Table 2).
We analyzed the clinical variables related to the best
intercept. Univariate analysis is demonstrated in Table 3.
Upon multivariate analysis, the risk of a worse intercept was
54% lower in the thymoglobulin group (odds ratio [OR]
0.46; 95% CI, 0.22–0.96; P .039), and a2-fold increased
risk among patients positive for viremia with CMV post-
transplantation (OR, 2.29; 95% CI, 1.09–4.81; P  .029).
DISCUSSION
Polyclonal antibodies such as thymoglobulin have been
traditionally employed for prophylaxis or treatment of
ARE.15 Our protocol included an intraoperative antibody
dose followed by sequential administrations seeking to
reduce the active circulating lymphocytes to mitigate the
effects of IRI. We sought to study the benefits for graft
function of induction therapy among patients who received
kidneys from deceased donors and after prolonged cold
ischemia time, a group with an high incidence of DGF. In
our sample, intraoperative administration of thymoglobulin
did not prevent DGF occurrence. Comparing low immuno-
logic risk patients, Goggins et al9 showed that intraopera-
tive but not postoperative administration of thymoglobulin
reduced the incidence of DGF (P  .001). The most
important characteristic of our population was the average
cold ischemia time of about 24 hours compared with 13
hours in the cited study. Thus, immunoprophylaxis with
thymoglobulin did not prevent DGF in the presence of
prolonged cold ischemia, as demonstrated in some earlier
trials wherein cold times were similar to the present
study.10,16
We confirmed a marked reduction in ARE among pa-
tients who were administered thymoglobulin. Induction has
also been claimed to improve graft survival.10,16 The use of
TG reduced combined outcomes including ARE by ap-
roximately 20%.17 The protective effect of Thymoglobulin
against ARE is superior compared with other agents such as
antithymocyte globulin (ATGAM) or basiliximab.10,16,17
Although not reducing DGF incidence, we were inter-
ested in observing the impact of thymoglobulin on graft
Table 2. Baseline Characteristics Among Patients Without
an ARE
Variables
Thymoglobulin
(n  89)
Control
(n  80) P
Age (yrs) 45.3  11.9 45.7  14.3 .87
Gender, male (%) 50.5 57.5 .71
Donor age (yrs) 37.4  15.3 40.1  14.8 .24
Donor gender, male (%) 47.2 36.2 .43
PRA 10.9  21.0 5.2  12.5 .08
MM 2.9  1.1 3.0  1.4 .55
Time on dialysis (mos) 45.0  33.6 45.5  25.5 .91
CIT (h) 22.3  7.0 21.3  7.5 .38
Tac/Cya (%) 44.9/46.0 47.5/46.2 .98Abbreviations: PRA, panel-reactive antibody; MM, missmatches; CIT, cold
ischemia time; Tac, tacrolimus; Cya, cyclosporine.unction. Taking into consideration the principles of pro-
ression of renal disease, we used 2 concepts to assess the
volution of graft function13: Intercept and slope. The
intercepts at 1 and 2 years were significantly better among
thymoglobulin than control patients. Likewise, patients who
received thymoglobulin, regardless of the lower incidence
of ARE, showed a better intercept over the same periods.
Multivariate analysis showed the variables related to a
negative slope to be occurrence of an ARE and female
recipients.14,18 When we assessed factors related to better
graft function at 1 year, the use of thymoglobulin proved to
be an independent factor determining the best function.
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